США - англійська - NLM (National Library of Medicine)

american health packaging - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 15 mg - oral olanzapine is indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see clinical studies ( 14.1)]. when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions ( 5.5)]. oral olanzapine is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in three clinical trials in adult patients with manic or mixed epi

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - olanzapine, quantity: 7.5 mg - tablet, film coated - excipient ingredients: crospovidone; lactose monohydrate; hyprolose; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - treatment of schizophrenia and related psychoses. short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - olanzapine, quantity: 5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; hyprolose; lactose monohydrate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - treatment of schizophrenia and related psychoses. short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - olanzapine, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hyprolose; magnesium stearate; crospovidone; microcrystalline cellulose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - treatment of schizophrenia and related psychoses. short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - olanzapine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; hyprolose; microcrystalline cellulose; lactose monohydrate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - treatment of schizophrenia and related psychoses. short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

США - англійська - NLM (National Library of Medicine)

ascend laboratories, llc - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 2.5 mg - oral olanzapine is indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see clinical studies (14.1)].       when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions (5.5)]. monotherapy — oral olanzapine is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in three clinical trials in adult patients with manic or mi

Бельгія - голландська - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - olanzapine 2,5 mg - tablet - 2,5 mg - olanzapine 2.5 mg - olanzapine

Бельгія - голландська - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - olanzapine 5 mg - tablet - 5 mg - olanzapine 5 mg - olanzapine

Бельгія - голландська - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - olanzapine 7,5 mg - tablet - 7,5 mg - olanzapine 7.5 mg - olanzapine

Бельгія - голландська - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - olanzapine 10 mg - tablet - 10 mg - olanzapine 10 mg - olanzapine